To the Editor:
We read with interest the recent article by Kawamura et al. [1] . The authors examined clinicopathologic findings of 112 patients with mucinous gastric carcinoma (MGC) and compared them with those of 4160 patients with nonmucinous gastric carcinoma (NGC). They showed that the overall 5-year survival rate of the MGC group was lower than that of the NGC group (65% vs 76%), because the MGC patients had advanced-stage tumors more frequently than the NGC patients. The characteristics of MGC, compared with NGC, included larger size, deeper invasion, and more advanced stage. These findings are in agreement with those of our recent study on MGC [2] .
To clarify the biologic behavior of MGC, treatment results must be compared among the same stages. Kawamura et al. [1] clearly showed that the survival rates compared in the same stages were not different between the MGC and NGC groups. We consider that this finding is important and useful. In our studies, the survival rate of MGC patients did not differ from that of NGC patients when compared in the same category of tumor size, depth of wall invasion, lymph node metastasis, and stage of disease [2, 3] . On a multivariate analysis, mucinous histologic type was not an independent prognostic factor [2] . Therefore, if MGC was considered to be more malignant, it would be because MGC was detected mostly in an advanced stage and rarely in an early stage [4] .
Kawamura et al. [1] concluded that "lymph node metastasis should be suspected when MGC invades to the submucosa or deeper". This statement is incorrect and misleading. In their study, the frequency of lymph node metastasis was not different between the MGC and NGC invading the muscularis propria, subserosa, serosa, and adjacent tissue [1, Fig. 3 ]. Although the frequency of lymph node metastasis for the MGC invading the submucosa was higher than that for the NGC invading the submucosa (4/15 ϭ 27% vs 9%), the latter
